Fig. 3.

Proliferation of the LNCaP95 clones in response to androgen, ralaniten, and enzalutamide. Parental LNCaP95 cells and clones were treated with R1881 (0.1 nM), EPI-002 (25 μM), enzalutamide (ENZ, 10 μM), or vehicle for a 4, or b 5 days, and then labeled with BrdU for 2 hrs. Data shown represents BrdU incorporation determined by ELISA after normalizing to the vehicle control and represent the mean ± SE, n=3. Statistical significance was determined by two-way ANOVA using the Dunnett multiple comparisons test